Evaluation Of The Provision Of Single Use Citric Acid Sachets To ...

24the era of needle/syringe exchange.” Scandinavian Journal of Infectious Diseases 33 (6):457-461Goldste in, A. C linton suppo rts needle ex change s but not funding. Washington Post. April21, 1998: A1Hagan, H., et al (1991). “The incidence of HBV infection and syringe exchange programs.”JAMA 266: 1646-1647Hagan, H., et a l (1993). “An inte rvie w study of pa rticipa nts in the Ta coma, Washington,syringe exchange.” Addiction 88: 1694-1695Hagan, H, D. C. Des Jarlais, S. R. Friedman, D. Purchase, & M. J. Alter (1995). “Reducedrisk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringeexchange program.” American Journal of Public Health 85: 1531-1537Harris, L. A. (1997). American Bar Association Report on Endorsing Needle Exchange.August 1997Hay, G & M. McKeganey (2001). “The attendance pattern of clients at a Scottish needleexchange.” Addiction 96 (2): 259-266He imer,R. K., & M. Lopes (1994). “Needle ex change in Ne w Ha ve n re duces HIV risks,promotes entry into drug treatment, and does not create new drug injectors.” JAMA271:1825-1826Heimer, R. K., et al (1994). “Three years of needle exchange in New Haven: what have welearned?” AIDS and Public Policy Journal 9:59-74He imer, R , K. Khoshnood, F. B. Ja riwa la, B. Dunca n, & Y. Ha rima (1996). “He pa titis inused syringes: the limits of sensitivity of techniques to detect HBV DNA, HCV RNA, andantibodies to HB core and HCV antigens.” Journal of Infectious Diseases 173: 997-1000Heimer, R. et al (1998). “Syringe use and reuse: effects of syringe exchange programs infour cities.” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology18 (Supp. 1): S37-S44Hellinger, F. K. (1992). “Forecasts of the costs of medical care for persons with HIV:1992-1995.” Inquiry 29: 356Holtgrave, D. R., & S. D. Pinkerton (1997). “Updates of cost of illness and quality of lifeestimates for use in economic evaluations of HIV prevention programs.” Journal ofAcquired Immune Deficiency Syndromes and Human Retrovirology 16: 54-62Hope, V. D., et al (2001). “Prevalence of hepatitis C among injection drug users inEngland and Wales: is harm reduction working?” American Journal of Public Health 91:38-42Hunter, G. M., et al (2000). “Measuring injecting risk behaviour in the second decade ofharm reduction: a survey of injecting drug users in England.” Addiction 95(9): 1351-1361Hurley, S. F., D. J. Jolley, & J. M. Kaldor (1997). “Effectiveness of needle-ex changeprogrammes for prevention of HIV infection.” Lancet 349: 1797-1800Hutchinson, S. J., A. Taylor, D. J. Goldberg, & L Gruer (2000). “Factors associated withinjecting risk behaviour among serial community-wide samples of injecting drug users in